| Martin D. Burke | Synthesis and study of small molecules with protein-like functions; molecular prosthetics; synthesis of complex natural products; iterative cross-coupling; MIDA boronates |
| Jefferson Chan | Development of chemical biology tools to study human disease states; synthesis of biomarker-responsive platforms and drugs for on-demand treatment |
| Hee-Sun Han | High-throughput, high-resolution omics technologies; microfluidics-based single virus genomics; imaging-based spatial transcriptomics; synthetic cell assembly; systems biology in brains and microbial populations |
| Paul J. Hergenrother | Use of small molecules to identify and define novel targets for the treatment of cancer and drug-resistant bacteria |
| Joomyung (Vicky) Jun | Developing modular chemical tools (i) to reversibly modify proteins for in vivo protein-based drug delivery; (ii) to investigate the cellular uptake mechanism of biologics; and (iii) for in vivo molecular imaging and new target discovery |
| Xiaotang Lu | Brain circuit imaging for understanding development and pathology of the central nervous system: correlated multidimensional (from nanoscale to whole brains) and multiplexed (transcriptomic and proteomic) imaging of the brain; (bio)chemical probes; tissue chemistry; imaging methods |
| Zaida Luthey-Schulten | Integration of experiments, theory, and simulations into whole-cell models; stochastic simulations of biological processes in minimal cells; physics of metabolism and ribosome biogenesis; dynamical networks of protein-nucleic acid interactions; statistical mechanics of the genome and DNA replication |
| Anastasia C. Manesis | Using the bioinorganic toolbox for understanding metallocofactor versatility in nature; bioinformatic approaches for identifying novel metallocofactors within unexplored protein families; diheme enzymes for oxygen activation; kynurenine-containing metalloproteins |
| Angad P. Mehta | Developing and using synthetic biology (i) to combat emerging viral pathogens and drug resistant bacteria; (ii) for directed endosymbiosis (an engineered, symbiotic cell within a host cell) to develop platforms for evolutionary studies and photosynthetic biosynthesis; and (iii) for engineering selectivity in targeting cancer |
| Liviu M. Mirica | Development of bifunctional therapeutic and diagnostic agents for amyloid peptide disorders such as Alzheimer’s disease; study of the role of transition metal ions in neurodegenerative diseases |
| Lisa Olshansky | Development, study, and application of switchable artificial metalloproteins as paradigms for enzyme mechanism and for development of new biocatalysts and biosensors |
| Mei Shen | Inflammation; immune response; Alzheimer’s disease; glioblastoma; gut-brain axis; environmental toxicology; plant biology; creating nano-resolved platforms to quantify signaling molecules and proteins in single cells, at single synaptic clefts, in tissues, and in mice brains; neurotransmission |
| Scott K. Silverman | DNA as an enzyme |
| Jonathan V. Sweedler | Neurochemistry: the characterization of unusual neurotransmitters and neuromodulators and the determination of their function |
| Wilfred A. van der Donk | Antibiotic biosynthesis; combinatorial chemistry of phosphonates; enzymology; genome mining for new natural products |